MISSION® pLKO.1-puro Luciferase shRNA Control Transduction Particles

shRNA sequence targeting luciferase

MISSION TurboGFP Control Transduction Particles
Pricing and availability is not currently available.

product line



≥1x106 VP/ml (via p24 assay)


capture ELISA: 106 TU/mL using p24

shipped in

dry ice

storage temp.


Looking for similar products? Visit Product Comparison Guide

General description

The MISSION Luciferase shRNA Control Transduction Particles contain an shRNA sequence targeting Luciferase, Photinus pyralis (GenBank Accession No. M15077). The Luciferase shRNA Control Particles are useful as a positive knockdown control in experiments using cell lines expressing firefly luciferase.
The Luciferase shRNA control transduction particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro-luciferase shRNA (Prod. No. SHC007). Self-inactivating replication incompetent viral particles are produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. In addition, the control transduction particles are pseudotyped with an envelope G glycoprotein from Vesicular Stomatitis Virus (VSV-G), allowing transduction of a wide variety of mammalian cells. 200 μl of 106 TU/ml (via p24 titering assay) lentiviral particles are provided as frozen stock.
When conducting experiments using MISSION® shRNA clones, the proper controls should be a key element of your experimental design to allow for accurate interpretation of knockdown results. The MISSION Control Transduction Particles are a critical positive control to monitor transduction efficiency.
To see more application data, protocols, vector maps visit


To see more application data, protocols, vector maps visit

Legal Information

MISSION is a registered trademark of Sigma-Aldrich Co. LLC

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


UN 3245 9

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

M N Khan et al.
British journal of cancer, 104(7), 1151-1159 (2011-03-10)
Clear cell renal cell carcinoma (CCRCC) is the commonest form of kidney cancer. Up to 91% have biallelic inactivation of VHL, resulting in stabilisation of HIF-α subunits. Factor inhibiting HIF-1 is an enzyme that hydroxylates HIF-α subunits and prevents recruitment...
Mariano J Alvarez et al.
Nature genetics, 50(7), 979-989 (2018-06-20)
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins...
Krijn R Vrijsen et al.
Advanced healthcare materials, 5(19), 2555-2565 (2016-08-30)
To date, cellular transplantation therapy has not yet fulfilled its high expectations for cardiac repair. A major limiting factor is lack of long-term engraftment of the transplanted cells. Interestingly, transplanted cells can positively affect their environment via secreted paracrine factors...
Ruth S Cruz Cosme et al.
Journal of virology, 83(7), 2839-2850 (2009-01-16)
Human cytomegalovirus (HCMV), a member of the beta subgroup of the family Herpesviridae, causes serious health problems worldwide. HCMV gene expression in host cells is a well-defined sequential process: immediate-early (IE) gene expression, early-gene expression, DNA replication, and late-gene expression....
Veena Padmanaban et al.
Nature, 573(7774), 439-444 (2019-09-06)
Metastasis is the major driver of death in patients with cancer. Invasion of surrounding tissues and metastasis have been proposed to initiate following loss of the intercellular adhesion protein, E-cadherin1,2, on the basis of inverse correlations between in vitro migration...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.